June 13, 2000Neurology
Injecting rationale into interferon-β therapy
Key result
Three clinically approved interferon-beta preparations were compared for their capacity to induce MxA in vitro and in vivo to clarify their biologic and therapeutic efficacy.
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
This editorial discusses the challenges of comparing different interferon-beta preparations for multiple sclerosis and highlights a study measuring MxA induction as a potential biomarker for biologic efficacy.
PICO
P
Population
Multiple Sclerosis
I
Intervention / Comparator
Interferon-β (IFNβ) preparations
O
Primary Outcome
Induction of MxA in vitro and in vivo
This editorial discusses the challenges of comparing different interferon-beta preparations for multiple sclerosis and highlights a study measuring MxA induction as a potential biomarker for biologic efficacy.
Limitations
- Direct comparison of different clinical trials is problematic because of their variation in design and control groups, and differences in type, dose, and route of IFN administration.
Cite This Study
Reder et al. (2000) conducted an editorial in Multiple Sclerosis. Interferon-β (IFNβ) preparations was evaluated on Induction of MxA in vitro and in vivo. Three clinically approved interferon-beta preparations were compared for their capacity to induce MxA in vitro and in vivo to clarify their biologic and therapeutic efficacy.